CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Preestablished Immunity

CD20 靶向治疗可消除疫苗接种后的新生抗体反应,但保留预先建立的免疫力

阅读:5
作者:Tanaya Shree, Vishnu Shankar, Julian J K Lohmeyer, Debra K Czerwinski, Joseph G Schroers-Martin, Gladys M Rodriguez, Sara Beygi, Alyssa M Kanegai, Karen S Corbelli, Etelka Gabriel, David M Kurtz, Michael S Khodadoust, Neel K Gupta, Lauren S Maeda, Ranjana H Advani, Ash A Alizadeh, Ronald Levy

Significance

In a large cohort of patients with B-cell lymphoma, time since anti-CD20 treatment was an independent predictor of neutralizing antibody response to COVID-19 vaccination. Comparing patients who received anti-CD20 treatment before or after vaccination, we demonstrate that vaccinating first can generate an antibody response that endures through anti-CD20-containing treatment. This article is highlighted in the In This Issue feature, p. 85.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。